Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Vertex Pharmaceutic (VRTX)

Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 117,917,328
  • Shares Outstanding, K 258,053
  • Annual Sales, $ 9,869 M
  • Annual Income, $ 3,620 M
  • 60-Month Beta 0.39
  • Price/Sales 11.79
  • Price/Cash Flow 31.18
  • Price/Book 6.37
Trade VRTX with:

Options Overview Details

View History
  • Implied Volatility 21.41% ( +3.45%)
  • Historical Volatility 17.13%
  • IV Percentile 14%
  • IV Rank 22.53%
  • IV High 34.35% on 01/16/24
  • IV Low 17.64% on 05/16/24
  • Put/Call Vol Ratio 1.46
  • Today's Volume 2,761
  • Volume Avg (30-Day) 2,736
  • Put/Call OI Ratio 1.16
  • Today's Open Interest 41,794
  • Open Int (30-Day) 40,335

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 30 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate 3.70
  • Number of Estimates 11
  • High Estimate 4.15
  • Low Estimate 3.22
  • Prior Year 3.53
  • Growth Rate Est. (year over year) +4.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
391.70 +14.09%
on 04/30/24
457.66 -2.36%
on 05/24/24
+49.40 (+12.43%)
since 04/26/24
3-Month
391.01 +14.29%
on 04/18/24
457.66 -2.36%
on 05/24/24
+19.91 (+4.66%)
since 02/28/24
52-Week
320.01 +39.65%
on 06/01/23
457.66 -2.36%
on 05/24/24
+116.89 (+35.42%)
since 05/26/23

Most Recent Stories

More News
Stock market today: Asian shares decline after a mixed post-holiday session on Wall Street

Asian shares are mostly lower after a mixed session on Wall Street

$SPX : 5,306.04 (+0.02%)
$DOWI : 38,852.86 (-0.55%)
$IUXX : 18,869.44 (+0.32%)
VRTX : 446.88 (-2.20%)
MRNA : 153.20 (-8.05%)
GME : 23.78 (+25.16%)
TMUS : 167.31 (+0.79%)
Got $500? 3 Pharma Stocks to Buy and Hold Forever

These players might even beat the market when the conditions are right.

VRTX : 446.88 (-2.20%)
LLY : 807.86 (+0.05%)
PFE : 28.30 (-2.01%)
Is It Too Late to Buy Vertex Pharmaceuticals Stock?

Shares of the growing biotech company have doubled in three years.

VRTX : 446.88 (-2.20%)
2 Biotech Stocks to Buy in May

You could buy these in any month, really.

VRTX : 446.88 (-2.20%)
REGN : 973.16 (-1.20%)
3 High-Flying Stocks That Could Soar Even More

The momentum should continue for Eli Lilly, Novo Nordisk, and Vertex Pharmaceuticals.

LLY : 807.86 (+0.05%)
NVO : 134.08 (-1.44%)
VRTX : 446.88 (-2.20%)
Is CRISPR Stock Going to $95? 1 Wall Street Analyst Thinks So.

How much would you pay for a stock that might earn $25 a year in six years?

CRSP : 54.84 (-0.72%)
VRTX : 446.88 (-2.20%)
Vertex Pharmaceuticals Is Racing Towards a New Blockbuster: Why the Stock Is a Smart Buy

The biotech's shares dropped following its latest quarterly update, but that shouldn't matter to long-term investors.

VRTX : 446.88 (-2.20%)
2 Unbelievable Growth Stocks You Can Buy and Hold for the Next Decade

These companies are raking in profits at astonishing clips.

VRTX : 446.88 (-2.20%)
ELF : 193.24 (+0.95%)
5 Reasons Vertex Pharmaceuticals Is a Screaming Buy on the Dip

New drugs in development and a lack of significant patent cliffs ahead make this a great pharma stock to buy now and hold over the long run.

VRTX : 446.88 (-2.20%)
Vertex Pharmaceuticals (VRTX) Q1 2024 Earnings Call Transcript

VRTX earnings call for the period ending March 31, 2024.

VRTX : 446.88 (-2.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company's main area of focus is cystic fibrosis. The company's lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi and Kalydeco, which...

See More

Key Turning Points

3rd Resistance Point 462.28
2nd Resistance Point 458.53
1st Resistance Point 452.71
Last Price 446.88
1st Support Level 443.14
2nd Support Level 439.39
3rd Support Level 433.57

See More

52-Week High 457.66
Last Price 446.88
Fibonacci 61.8% 405.08
Fibonacci 50% 388.84
Fibonacci 38.2% 372.59
52-Week Low 320.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar